Sbir FY25 concept award, development of an immunotherapy for ewing sarcoma using a novel murine model
Active Definitive Contract Awarded Last action
- Contract number
- 75N91025C00025
- Awardee
-
Merlin Biotech Inc. UEI U33SZN8R3966
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $300,000
Award facts
- Opportunity
-
- National Cancer Institute (NCI) Small Business Innovation Research (SBIR) Innovative Concept Award Program – Fiscal Year 2025 Pre-Solicitation · 75N91024R00013 · Posted Mar 28, 2024
- Contract value 100% obligated
- $300,000.00 Current and potential, with all options
- Completion date 53% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- Total Small Business
- Competition
- Full and Open Competition after exclusion of sources · 55 offers Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Philadelphia, PA 19104, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | -$55,000 | |
| Original award | $355,000 |
About this award
The National Cancer Institute awarded a $300,000 firm fixed-price definitive contract to Merlin Biotech Inc. for development of an immunotherapy for Ewing sarcoma using a novel murine model on September 22, 2025, under a total small business set-aside.
This award is an SBIR FY25 Concept Award. The originating solicitation sought proposals from small businesses to develop innovative and transformative technologies for the treatment, detection, and diagnosis of pediatric and rare cancers, with requirements for initial proof-of-concept data, anticipated product identification, and a commercialization plan. Place of performance is Philadelphia, PA. The contract performance period extends through September 21, 2027.
Quick answers
Who was awarded contract 75N91025C00025?
75N91025C00025 was awarded to Merlin Biotech Inc. by National Cancer Institute (National Institutes of Health) on September 22, 2025.
How much is contract 75N91025C00025 worth?
The government has obligated $300,000 on 75N91025C00025.
Was contract 75N91025C00025 competed?
The extent of competition for 75N91025C00025 was full and open competition after exclusion of sources. The government received 55 offers. It was set aside: Total Small Business.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award